Eagle Pharmaceuticals (EGRX) Reports Q2 Loss of $0.12

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of ($0.12). Revenue for the quarter came in at $48.71 million versus the consensus estimate of $53.87 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• PG&E Corp, Edison spike on chatter
• S&P Weighs Multibillion-Dollar Spinout of Data Platform CapIQ - Bloomberg
• Action Behavior Centers' Family Advocacy Team Meets with Congressional Leaders in Washington, D.C., to Discuss Access to ABA Therapy for Autism